---
title: "LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648897.md"
description: "LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Savara (SVRA) with a price target of $9.00. The overall analyst consensus for Savara is a Strong Buy, with an average price target of $11.00. Brisebois has a 40.11% success rate on his stock recommendations."
datetime: "2026-05-16T14:36:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648897.md)
  - [en](https://longbridge.com/en/news/286648897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648897.md)
generator: "portal-rs"
---

# LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Savara today and set a price target of $9.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics. According to TipRanks, Brisebois has an average return of 2.4% and a 40.11% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara with a $11.00 average price target.

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)

## Related News & Research

- [Savara Q2 loss widens as operating expenses rise](https://longbridge.com/en/news/295574578.md)
- [SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market](https://longbridge.com/en/news/295577539.md)
- [Assessing Savara (SVRA) Valuation After Accelerated Review Progress For MOLBREEVI](https://longbridge.com/en/news/281956853.md)
- [Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI](https://longbridge.com/en/news/295577813.md)
- [Savara (SVRA) Gets a Buy from LifeSci Capital](https://longbridge.com/en/news/280029470.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**